Xenon anesthesia for awake craniotomy: safety and efficacy.


Journal

Minerva anestesiologica
ISSN: 1827-1596
Titre abrégé: Minerva Anestesiol
Pays: Italy
ID NLM: 0375272

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 24 7 2018
medline: 12 3 2020
entrez: 24 7 2018
Statut: ppublish

Résumé

The asleep-awake-asleep (AAA) craniotomy is a technique that offers the opportunity of having a patient fully cooperative during the awake phase, and minimizes the possible discomfort, due to the asleep phase. The aim of this prospective observational study was to test the use of xenon in the first asleep phase of an AAA craniotomy, in patients undergoing craniotomy for brain tumor resection. The data have been collected from 40 awake craniotomy procedures, performed in patients with cerebral tumor, treated with the AAA technique. Patients were treated with xenon during the asleep phase, and quality of mapping, complications and qualitative judgment of the experience given by the patients were recorded. The mapping was carried out as planned in 37 out of 40 cases. The doses of xenon administered during the first asleep phase of the anesthesia was 13±2 L. Time for awakening after xenon was switched off was 5±1 minute. A combination of xenon and regional anesthesia (with no need for additional systemic anesthetics) was adequate to accomplish craniotomy in 27/40 patients (67.5%). On the day after the operation, 37 patients recalled the testing procedure for mapping during the awake period, none had recollection of local anesthetic injections for regional anesthesia or sound associated with the neurosurgical drill. Five patients (12.5%) reported mild pain during tumor removal (VAS Score less than three). In this case series, xenon anesthesia was successfully used for the sedative phase of an awake craniotomy accomplished with an AAA approach.

Sections du résumé

BACKGROUND
The asleep-awake-asleep (AAA) craniotomy is a technique that offers the opportunity of having a patient fully cooperative during the awake phase, and minimizes the possible discomfort, due to the asleep phase. The aim of this prospective observational study was to test the use of xenon in the first asleep phase of an AAA craniotomy, in patients undergoing craniotomy for brain tumor resection.
METHODS
The data have been collected from 40 awake craniotomy procedures, performed in patients with cerebral tumor, treated with the AAA technique. Patients were treated with xenon during the asleep phase, and quality of mapping, complications and qualitative judgment of the experience given by the patients were recorded.
RESULTS
The mapping was carried out as planned in 37 out of 40 cases. The doses of xenon administered during the first asleep phase of the anesthesia was 13±2 L. Time for awakening after xenon was switched off was 5±1 minute. A combination of xenon and regional anesthesia (with no need for additional systemic anesthetics) was adequate to accomplish craniotomy in 27/40 patients (67.5%). On the day after the operation, 37 patients recalled the testing procedure for mapping during the awake period, none had recollection of local anesthetic injections for regional anesthesia or sound associated with the neurosurgical drill. Five patients (12.5%) reported mild pain during tumor removal (VAS Score less than three).
CONCLUSIONS
In this case series, xenon anesthesia was successfully used for the sedative phase of an awake craniotomy accomplished with an AAA approach.

Identifiants

pubmed: 30035455
pii: S0375-9393.18.12406-0
doi: 10.23736/S0375-9393.18.12406-0
doi:

Substances chimiques

Anesthetics, Inhalation 0
Xenon 3H3U766W84

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

148-155

Commentaires et corrections

Type : CommentIn

Auteurs

Alexander Kulikov (A)

Department of Anesthesiology, Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia - akulikov@nsi.ru.

Federico Bilotta (F)

Department of Anesthesiology, Critical Care and Pain Medicine, Sapienza University, Rome, Italy.

Beatrice Borsellino (B)

Department of Anesthesiology, Critical Care and Pain Medicine, Sapienza University, Rome, Italy.

Denis Sel'kov (D)

Department of Anesthesiology, Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.

Grigory Kobyakov (G)

Department of Anesthesiology, Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.

Andrey Lubnin (A)

Department of Anesthesiology, Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH